REMARC

REMARC

Comparaison d’un traitement d’entretien par Lenalidomide versus placebo chez des patients agés atteints d’un Lymphome Diffus à Grandes Cellules B (DLBCL) et répondeurs à un traitement d’induction par chimiothérapie de type R-CHOP (phase III)

REMARC Synopsis final

Publications 2022

Lysa 2022_LYSA_Deep Learning approach to automatize TMTV calculation regardless of segmentation methodology for main FDG avid lymphomas
Wendy Revailler, Anne-Ségolène Cottereau, Cédric Rossi, Rudy Noyelle, Thomas Trouillard, Franck Morschhauser, Rene-Olivier Casasnovas, Catherine Thieblemont, Steven Le Gouill, Marc P-E André, Hervé Ghesquières, Romain Ricci, Michel Meignan, Salim Kanoun
Diagnostics (Basel) . 2022 Feb 6;12(2):417. En savoir plus
Lysa 2022_LYSA_A guide to ComBat harmonization of imaging biomarkers in multicenter studies
Fanny Orlhac, Jakoba J. Eertink, Anne-Ségolène Cottereau, Josée M. Zijlstra, Catherine Thieblemont, Michel Meignan, Ronald Boellaard, Irène Buvat
J Nucl Med . 2022 Feb;63(2):172-179. En savoir plus

Publications 2021

Lysa 2021_LYSA_Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Sophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, Samuel Griolet, Maria Gomes da Silva, Pierre Feugier, Franck Morschhauser, Judith Trotman, Loic Renaud, Richard Greil, Alejandro Martin Garcia-Sancho, Sebastian Grosicki, Koen van Eygen, Christiane Copie-Bergman, Corinne Haioun, Catherine Thieblemont
Blood Adv . 2021 Aug 10;5(15):2965-2968. En savoir plus
Lysa 2021_LYSA_Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
Nicolo Capobianco, Michel Meignan, Anne-Segolene Cottereau, Laetitia Vercellino, Ludovic Sibille, Bruce Spottiswoode, Sven Zuehlsdorff, Olivier Casasnovas, Catherine Thieblemont, and Irene Buvat
J Nucl Med . 2021 Jan;62(1):30-36. doi: 10.2967/jnumed.120.242412 En savoir plus
Lysa 2021_LYSA_New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT
Cottereau AS, Meignan M, Nioche C, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I.
Cancers (Basel) . 2021 Aug 8;13(16):3998. En savoir plus
Lysa 2021_LYSA_High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B
Camille Laurent, José Adélaïde, Arnaud Guille, Bruno Tesson, Elodie Gat, Solene Evrard, Frederic Escudié, Charlotte Syrykh, Danielle Canioni, Bettina Fabiani, Véronique Meignin, Catherine Chassagne-Clement , Peggy Dartigues, Alexandra Traverse-Glehen, Marie Parrens, Sarah Huet, Christiane Copie-Bergman, Gilles Salles, Daniel Birnbaum, Pierre Brousset, Franck Morschhauser, Luc Xerri, Lymphoma Study Association (LYSA)
Am J Surg Pathol . 2021 Oct 1;45(10):1324-1336. En savoir plus

Publication 2020

Lysa 2020_LYSA_Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
A S Cottereau, M Meignan, C Nioche, N Capobianco, J Clerc, L Chartier, L Vercellino, O Casasnovas, C Thieblemont, I Buvat
Ann Oncol . 2020 Dec 2;S0923-7534(20)43174-6. doi: 10.1016/j.annonc.2020.11.019. En savoir plus
Communication orale REMARC ICMLugano 2021
Catherine Thieblemont

Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study)

 

ICMLugano Catherine Thieblemont Abstract N°017

 

Posters REMARC ICMLugano 2021
Catherine Thieblemont

Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study

 

ICMLugano Catherine Thieblemont Abstract N°091

Catherine Thieblemont

High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS – From the REMARC study

 

ICMLugano Catherine Thieblemont Abstract N°166